ACLARIS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.17 USD | -4.10% |
|
-4.88% | +11.43% |
| Mar. 19 | Aclaris Therapeutics, Inc. Announces Board Resignations | CI |
| Feb. 27 | Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 7.76M | Sales 2025 * | 8.69M | Capitalization | 86.53M |
|---|---|---|---|---|---|
| Net income 2024 * | -73M | Net income 2025 * | -70M | EV / Sales 2024 * | 1.97 x |
| Net cash position 2024 * | 71.24M | Net cash position 2025 * | 157M | EV / Sales 2025 * | -8.16 x |
| P/E ratio 2024 * |
-1.2
x | P/E ratio 2025 * |
-1.29
x | Employees | 89 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aclaris Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -4.10% | ||
| 1 week | -4.10% | ||
| Current month | -5.65% | ||
| 1 month | +1.74% | ||
| 3 months | -8.59% | ||
| 6 months | -76.51% | ||
| Current year | +11.43% |
1 week
1.14
1.26
1 month
1.141.32
Current year
0.861.51
1 year
0.5911.12
3 years
0.5926.50
5 years
0.5930.38
10 years
0.5933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Neal Walker
CEO | Chief Executive Officer | 54 | 12-06-30 |
Kevin Balthaser
DFI | Director of Finance/CFO | - | 16-12-31 |
Ajay Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Schiff
BRD | Director/Board Member | 58 | 17-08-08 |
Maxine Gowen
BRD | Director/Board Member | 66 | 19-07-01 |
Andrew Powell
BRD | Director/Board Member | 66 | 17-01-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.17 | -4.10% | 1,439,407 |
| 24-04-23 | 1.22 | 0.00% | 637,744 |
| 24-04-22 | 1.22 | -1.61% | 663,173 |
| 24-04-19 | 1.24 | +0.81% | 579,779 |
| 24-04-18 | 1.23 | 0.00% | 645,828 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
1.22
USD
Average target price
1.8
USD
Spread / Average Target
+47.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.43% | 86.53M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- ACRS Stock
